Synthetic retinoid fenretinide in breast cancer chemoprevention

被引：22

作者：

Bonanni, Bernardo ^{[1
]}

Lazzeroni, Matteo ^{[1
]}

Veronesi, Umberto ^{[1
]}

机构：

[1] European Inst Oncol, Div Canc Prevent & Genet, I-20141 Milan, Italy

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2007年 / 7卷 / 04期

关键词：

breast neoplasm; chemoprevention; clinical trial; fenretinide; retinoid;

D O I：

10.1586/14737140.7.4.423

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Preclinical models suggest that retinoids inhibit mammary carcinogenesis. The induction of apoptosis is a unique feature of fenretinide, the most-studied retinoid in clinical trials of breast cancer chemoprevention, owing to its selective accumulation in breast tissue and its favorable toxicological profile. In a Phase III breast cancer prevention trial, fenretinide showed a strong trend of reduction of incidence of second breast malignancies in premenopausal women, which was confirmed by 15 years of follow-up. This warrants further research on the mechanisms of action and potential efficacy of fenretinide and provides the rationale for a Phase III primary prevention trial in young women at high risk for breast cancer. This review will highlight the role of fenretinide in breast cancer chemoprevention.

引用

页码：423 / 432

页数：10

共 102 条

[1]

[Anonymous], CANC FACTS FIG 2007

[2] Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators [J].